We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

60 hedge funds and large institutions have $173M invested in Xenon Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

0.73% less ownership

Funds ownership: 68.88% → 68.15% (-0.73%)

4% less capital invested

Capital invested by funds: $180M → $173M (-$7.03M)

5% less funds holding

Funds holding: 63 → 60 (-3)

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
60
Holders Change
-3
Holders Change %
-4.76%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
8
Increased
18
Reduced
13
Closed
10
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$9K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$6.25M
2
Bank of New York Mellon
Bank of New York Mellon
New York
+$2.18M
3
NMC
NEA Management Company
Maryland
+$1.75M
4
ACP
Acuta Capital Partners
California
+$1.43M
5
Russell Investments Group
Russell Investments Group
United Kingdom
+$753K

Top Sellers

1
SFM
Sphera Funds Management
Israel
-$5.42M
2
SSA
Schonfeld Strategic Advisors
New York
-$5.08M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.05M
4
SCM
Stonepine Capital Management
Oregon
-$1M
5
IPC
Invesco Private Capital
New York
-$808K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$61K +$11.9K +1,241 +25%
UBS Group
52
UBS Group
Switzerland
$51K +$20.3K +2,123 +71%
CSS
53
Cubist Systematic Strategies
Connecticut
$44K -$25.7K -2,690 -38%
CFGS
54
Concourse Financial Group Securities
Alabama
$20K +$9.57K +1,000 +100%
Deutsche Bank
55
Deutsche Bank
Germany
$19K -$16.4K -1,719 -46%
Citigroup
56
Citigroup
New York
$10K +$2.35K +246 +33%
LC
57
Lindbrook Capital
California
$7K +$7.18K +750 New
Wells Fargo
58
Wells Fargo
California
$3K – – –
Daiwa Securities Group
59
Daiwa Securities Group
Japan
$2K – – –
SFM
60
Sphera Funds Management
Israel
– -$5.42M -533,655 Closed
SSA
61
Schonfeld Strategic Advisors
New York
– -$5.08M -500,000 Closed
SCM
62
Stonepine Capital Management
Oregon
– -$1M -98,860 Closed
IPC
63
Invesco Private Capital
New York
– -$808K -79,539 Closed
Two Sigma Investments
64
Two Sigma Investments
New York
– -$591K -58,149 Closed
Millennium Management
65
Millennium Management
New York
– -$491K -48,286 Closed
WG
66
Winton Group
United Kingdom
– -$132K -13,012 Closed
Goldman Sachs
67
Goldman Sachs
New York
– -$124K -12,246 Closed
TRCT
68
Tower Research Capital (TRC)
New York
– -$19K -1,870 Closed
Bank of America
69
Bank of America
North Carolina
– -$277 -29 -35%
1 2
3

XENE Hedge Fund Activity: Q2 2019 in Review

60 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2019, worth a combined $173M — down 3.9% from $180M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of XENE and 8 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 18 added.

The largest buyer was Eventide Asset Management, adding an estimated $6.25M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.42M sold.

  • 60 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2019, down from 63 in Q1 2019.
  • Funds reported $173M of Xenon Pharmaceuticals stock for Q2 2019, down 3.9% quarter-over-quarter.
  • 8 funds opened new Xenon Pharmaceuticals positions in Q2 2019 and 10 closed out, a net change of -2 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2019 was Eventide Asset Management, an estimated $6.25M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2019 was Sphera Funds Management, an estimated $5.42M sold.

Based on aggregated 13F filings for Q2 2019.